Symbols / PMCB
PMCB Chart
About
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.14M |
| Enterprise Value | -12.71M | Income | -7.63M | Sales | — |
| Book/sh | 5.25 | Cash/sh | 2.03 | Dividend Yield | — |
| Payout | 0.00% | Employees | 2 | IPO | — |
| P/E | — | Forward P/E | -1.86 | PEG | — |
| P/S | — | P/B | 0.13 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 13.06 |
| Current Ratio | 14.60 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.14 | EPS next Y | -0.38 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2022-09-14 16:00 | ROA | -4.76% |
| ROE | -17.68% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 10.13M |
| Shs Float | 9.36M | Short Float | 2.11% | Short Ratio | 0.46 |
| Short Interest | — | 52W High | 1.86 | 52W Low | 0.63 |
| Beta | 0.31 | Avg Volume | 3.66M | Volume | 105.17K |
| Target Price | — | Recom | None | Prev Close | $0.69 |
| Price | $0.70 | Change | 2.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.71
Latest analyst target
3. DCF / Fair value
$-13.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.71
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2021-11-08 | init | HC Wainwright & Co. | — → Neutral | — |
- PharmaCyte Biotech Inc. (PMCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Sat, 21 Feb 2026 00
- PMCB Stock Jumps 25% After Company Sells Stake In Femasys - Stocktwits ue, 25 Nov 2025 18
- PharmaCyte Biotech stock soars after successful Femasys stake sale - Investing.com ue, 25 Nov 2025 08
- Insider Purchase: CEO and President of $PMCB Buys 40,000 Shares - Quiver Quantitative Wed, 07 Jan 2026 08
- PMCB Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 00
- PharmaCyte Biotech’s Potential Explored Amidst Market Movements - timothysykes.com Fri, 05 Dec 2025 08
- PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN ue, 25 Nov 2025 19
- PharmaCyte Biotech (Nasdaq: PMCB) Now Holds ~$20M Cash, $25M in Marketable Securities - Stock Titan ue, 25 Nov 2025 08
- Thursday 1/8 Insider Buying Report: PMCB, COSM - Nasdaq hu, 08 Jan 2026 08
- PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing Investors - Investing News Network Fri, 12 Sep 2025 07
- PharmaCyte Biotech Inc. (PMCB) reports earnings - qz.com Mon, 17 Mar 2025 07
- PharmaCyte Biotech: Is Growth Here to Stay? - StocksToTrade hu, 04 Dec 2025 08
- AVXL Stock Jumps On Lower Q4 Loss, Anticipation For EMA Approval Of Alzheimer’s Drug - Stocktwits ue, 25 Nov 2025 08
- Momentum Shift: Will PMCB benefit from sector rotation - Rate Cut & Stepwise Trade Signal Implementation - mfd.ru Mon, 09 Feb 2026 03
- PMCB Stock Price and Chart — NASDAQ:PMCB - TradingView Wed, 11 Aug 2021 00
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 60000 | 48232 | — | Purchase at price 0.78 - 0.84 per share. | SCHECHTER JONATHAN L | Director | — | 2026-01-07 00:00:00 | D |
| 1 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | WEINSTEIN ROBERT | Director | — | 2025-12-12 00:00:00 | D |
| 2 | 37500 | — | — | Stock Award(Grant) at price 0.00 per share. | WALKER WAYNE REMELL | Director | — | 2025-12-12 00:00:00 | D |
| 3 | 150000 | — | — | Stock Award(Grant) at price 0.00 per share. | SCHECHTER JONATHAN L | Director | — | 2025-12-12 00:00:00 | D |
| 4 | 37500 | — | — | Stock Award(Grant) at price 0.00 per share. | ABECASSIS MICHAEL M. M.D. | Director | — | 2025-12-12 00:00:00 | D |
Financials
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 7.06M | 685.40K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -38.00M | -9.78M | -6.46M | -4.24M |
| TotalUnusualItems | 33.62M | 3.26M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 33.62M | 3.26M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 30.66M | 333.76K | -4.32M | -4.24M |
| EBITDA | -4.38M | -6.52M | -6.46M | -4.24M |
| EBIT | -4.38M | -6.52M | -6.46M | -4.24M |
| NetInterestIncome | 1.42M | 3.40M | 1.94M | 157.14K |
| InterestExpense | 0.00 | 509.00 | 3.05K | |
| InterestIncome | 1.42M | 3.40M | 1.94M | 157.65K |
| NormalizedIncome | 4.10M | -2.24M | -4.32M | -4.24M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 30.66M | 333.76K | -4.32M | -4.24M |
| TotalExpenses | 4.38M | 6.52M | 6.46M | 4.39M |
| TotalOperatingIncomeAsReported | -4.38M | -8.52M | -6.46M | -4.39M |
| DilutedAverageShares | 7.33M | 9.58M | 19.49M | 15.52M |
| BasicAverageShares | 7.33M | 9.58M | 19.49M | 15.52M |
| DilutedEPS | 3.19 | -1.80 | -0.22 | -0.27 |
| BasicEPS | 3.19 | -1.80 | -0.22 | -0.27 |
| DilutedNIAvailtoComStockholders | 23.36M | -17.24M | -4.32M | -4.24M |
| NetIncomeCommonStockholders | 23.36M | -17.24M | -4.32M | -4.24M |
| OtherunderPreferredStockDividend | 6.16M | 15.05M | 0.00 | |
| PreferredStockDividends | 1.13M | 2.52M | ||
| NetIncome | 30.66M | 333.76K | -4.32M | -4.24M |
| NetIncomeIncludingNoncontrollingInterests | 30.66M | 333.76K | -4.32M | -4.24M |
| NetIncomeContinuousOperations | 30.66M | 333.76K | -4.32M | -4.24M |
| PretaxIncome | 30.66M | 333.76K | -4.32M | -4.24M |
| OtherIncomeExpense | 33.62M | 3.45M | 202.00K | -4.28K |
| OtherNonOperatingIncomeExpenses | -965.00 | 191.15K | 202.00K | -4.28K |
| SpecialIncomeCharges | -2.02M | -3.57M | 0.00 | 0.00 |
| GainOnSaleOfPPE | 0.00 | -1.57M | 0.00 | |
| OtherSpecialCharges | 2.02M | -75.98K | ||
| WriteOff | 1.57M | 0.00 | ||
| ImpairmentOfCapitalAssets | 0.00 | 2.00M | 0.00 | |
| GainOnSaleOfSecurity | 35.64M | 6.84M | ||
| NetNonOperatingInterestIncomeExpense | 1.42M | 3.40M | 1.94M | 157.14K |
| InterestExpenseNonOperating | 0.00 | 509.00 | 3.05K | |
| InterestIncomeNonOperating | 1.42M | 3.40M | 1.94M | 157.65K |
| OperatingIncome | -4.38M | -6.52M | -6.46M | -4.39M |
| OperatingExpense | 4.38M | 6.52M | 6.46M | 4.39M |
| OtherOperatingExpenses | 1.32M | 1.23M | 1.54M | 1.43M |
| ResearchAndDevelopment | 438.42K | 407.43K | 468.54K | 690.94K |
| SellingGeneralAndAdministration | 3.94M | 6.11M | 4.75M | 2.16M |
| GeneralAndAdministrativeExpense | 3.94M | 6.11M | 4.75M | 2.16M |
| OtherGandA | 3.94M | 6.11M | 3.80M | 1.90M |
| SalariesAndWages | 1.14M | 951.35K | 256.49K | 273.23K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | |
|---|---|---|---|---|
| TreasurySharesNumber | 14.88M | 13.63M | 4.81M | |
| OrdinarySharesNumber | 6.80M | 8.04M | 16.79M | 20.72M |
| ShareIssued | 21.67M | 21.67M | 21.60M | 20.72M |
| TangibleBookValue | 50.34M | 26.10M | 69.14M | 86.37M |
| InvestedCapital | 51.89M | 27.65M | 72.69M | 89.92M |
| WorkingCapital | 19.46M | 43.02M | 67.56M | 84.79M |
| NetTangibleAssets | 50.34M | 37.97M | 69.14M | 86.37M |
| CommonStockEquity | 51.89M | 27.65M | 72.69M | 89.92M |
| PreferredStockEquity | 11.87M | |||
| TotalCapitalization | 51.89M | 39.51M | 72.69M | 89.92M |
| TotalEquityGrossMinorityInterest | 51.89M | 39.51M | 72.69M | 89.92M |
| StockholdersEquity | 51.89M | 39.51M | 72.69M | 89.92M |
| GainsLossesNotAffectingRetainedEarnings | -23.87K | -23.51K | -23.00K | -15.76K |
| OtherEquityAdjustments | -23.87K | -23.51K | -23.00K | -15.76K |
| TreasuryStock | 44.61M | 42.04M | 13.56M | 0.00 |
| RetainedEarnings | -84.97M | -115.63M | -115.96M | -111.65M |
| AdditionalPaidInCapital | 181.49M | 185.33M | 202.23M | 201.58M |
| CapitalStock | 2.17K | 11.87M | 2.16K | 2.07K |
| CommonStock | 2.17K | 2.17K | 2.16K | 2.07K |
| PreferredStock | 0.00 | 11.87M | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 3.28M | 20.39M | 586.58K | 704.37K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 363.00K | 12.97M | 0.00 | 0.00 |
| DerivativeProductLiabilities | 338.00K | 12.97M | 0.00 | |
| NonCurrentAccruedExpenses | 25.00K | 0.00 | ||
| CurrentLiabilities | 2.91M | 7.42M | 586.58K | 704.37K |
| OtherCurrentLiabilities | 6.30M | -1.00 | ||
| PayablesAndAccruedExpenses | 2.91M | 1.12M | 586.58K | 704.37K |
| CurrentAccruedExpenses | 2.49M | 395.13K | 400.20K | 499.01K |
| Payables | 424.63K | 729.44K | 186.38K | 205.36K |
| TotalTaxPayable | 25.42K | 340.07K | 58.10K | |
| AccountsPayable | 399.20K | 389.37K | 128.28K | 205.36K |
| TotalAssets | 55.17M | 59.90M | 73.28M | 90.62M |
| TotalNonCurrentAssets | 32.79M | 9.46M | 5.13M | 5.13M |
| OtherNonCurrentAssets | 7.69K | 7.69K | 7.69K | 7.69K |
| NonCurrentNoteReceivables | 0.00 | 2.75M | 0.00 | |
| FinancialAssets | 8.76M | 5.15M | 0.00 | |
| InvestmentsAndAdvances | 22.47M | 0.00 | 1.57M | 1.57M |
| GoodwillAndOtherIntangibleAssets | 1.55M | 1.55M | 3.55M | 3.55M |
| OtherIntangibleAssets | 1.55M | 1.55M | 3.55M | 3.55M |
| CurrentAssets | 22.38M | 50.44M | 68.15M | 85.49M |
| OtherCurrentAssets | 223.76K | 259.80K | 107.68K | |
| HedgingAssetsCurrent | 2.92M | 0.00 | ||
| PrepaidAssets | 107.68K | 94.17K | 73.13K | |
| Receivables | 3.70M | 0.00 | ||
| NotesReceivable | 3.70M | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 15.54M | 50.18M | 68.04M | 85.40M |
| OtherShortTermInvestments | 366.32K | 0.00 | ||
| CashAndCashEquivalents | 15.17M | 50.18M | 68.04M | 85.40M |
| CashFinancial | 2.20M |
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| FreeCashFlow | -2.98M | -2.15M | -3.79M | -4.12M |
| RepurchaseOfCapitalStock | -25.03M | -44.36M | -13.56M | 0.00 |
| RepaymentOfDebt | 0.00 | -50.80K | -62.44K | |
| IssuanceOfCapitalStock | 0.00 | 33.65M | 0.00 | 87.36M |
| InterestPaidSupplementalData | 0.00 | 1.60K | 800.00 | |
| IncomeTaxPaidSupplementalData | 0.00 | 1.60K | 0.00 | 509.00 |
| EndCashPosition | 15.17M | 50.18M | 68.04M | 85.40M |
| BeginningCashPosition | 50.18M | 68.04M | 85.40M | 2.20M |
| EffectOfExchangeRateChanges | -358.00 | -508.00 | -7.25K | 4.62K |
| ChangesInCash | -35.01M | -17.86M | -17.35M | 83.19M |
| FinancingCashFlow | -25.03M | -10.71M | -13.56M | 87.31M |
| CashFlowFromContinuingFinancingActivities | -25.03M | -10.71M | -13.56M | 87.31M |
| ProceedsFromStockOptionExercised | 0.00 | 70.00 | 880.00 | 0.00 |
| NetPreferredStockIssuance | -22.49M | 17.49M | 0.00 | |
| PreferredStockPayments | -22.49M | -16.16M | 0.00 | |
| PreferredStockIssuance | 0.00 | 33.65M | 0.00 | |
| NetCommonStockIssuance | -2.54M | -28.20M | -13.56M | 87.36M |
| CommonStockPayments | -2.54M | -28.20M | -13.56M | 0.00 |
| CommonStockIssuance | 0.00 | 87.36M | 4.70M | |
| NetIssuancePaymentsOfDebt | 0.00 | -50.80K | -62.44K | |
| NetLongTermDebtIssuance | 0.00 | -50.80K | -62.44K | |
| LongTermDebtPayments | 0.00 | -50.80K | -62.44K | |
| InvestingCashFlow | -7.00M | -5.00M | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | -7.00M | -5.00M | 0.00 | |
| NetOtherInvestingChanges | -5.00M | |||
| NetInvestmentPurchaseAndSale | -7.00M | 0.00 | 0.00 | |
| PurchaseOfInvestment | -7.00M | 0.00 | ||
| OperatingCashFlow | -2.98M | -2.15M | -3.79M | -4.12M |
| CashFlowFromContinuingOperatingActivities | -2.98M | -2.15M | -3.79M | -4.12M |
| ChangeInWorkingCapital | 1.36M | 298.89K | -297.17K | 9.04K |
| ChangeInOtherCurrentAssets | 0.00 | -316.00 | 0.00 | |
| ChangeInPayablesAndAccruedExpense | 1.32M | 451.01K | -283.66K | 30.40K |
| ChangeInAccruedExpense | 1.31M | 189.92K | -40.71K | -2.70K |
| ChangeInPayable | 9.84K | 261.09K | -242.95K | 33.10K |
| ChangeInAccountPayable | 9.84K | 261.09K | -242.95K | 33.10K |
| ChangeInPrepaidAssets | 36.04K | -152.12K | -13.51K | -21.04K |
| OtherNonCashItems | -21.23M | -195.00K | 174.02K | 34.85K |
| StockBasedCompensation | 478.64K | 674.69K | 645.41K | 77.96K |
| UnrealizedGainLossOnInvestmentSecurities | -6.07M | -1.09M | 0.00 | |
| AssetImpairmentCharge | 0.00 | 2.00M | 0.00 | |
| OperatingGainsLosses | -8.17M | -4.17M | -75.20K | |
| GainLossOnInvestmentSecurities | -8.17M | -5.75M | ||
| NetIncomeFromContinuingOperations | 30.66M | 333.76K | -4.32M | -4.24M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PMCB
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|